丙戊酸镁联合拉莫三嗪对癫痫患者生活质量及不良反应的影响

Effect of Magnesium Valproate Combined with Lamotrigine on the Quality of Life and Adverse Reactions of Patients with Epilepsy

目的探讨丙戊酸镁联合拉莫三嗪对癫痫患者生活质量及不良反应的影响。方法选取2014年7月~2017年3月本院87例癫痫患者,按照随机数表法分为观察组(n=44)与对照组(n=43)。对照组给予丙戊酸镁治疗,在此基础上观察组联合拉莫三嗪治疗,均连续治疗6个月。对比两组临床疗效、治疗前后生活质量(QOLIE-31)评分及不良反应发生率。结果与对照组比较,观察组疗效更为显著,且总有效率93.18%(41/44)较对照组76.74%(33/43)高,(P<0.05);两组QOLIE-31评分治疗前比较无显著差异(P>0.05),治疗后较治疗前均显著改善(P<0.05),且观察组高于对照组(P<0.05);观察组恶心/呕吐、腹泻、畏食、头晕/头痛等发生率与对照组比较无显著差异(P>0.05)。结论给予癫痫丙戊酸镁联合拉莫三嗪治疗,疗效显著,可有效改善患者生活质量,且具有一定安全性。

Objective To investigate the effect of magnesium valproate combined with lamotrigine on the quality of life and adverse reactions of patients with epilepsy. Methods 87 cases of epilepsy from July 2014 to March 2017 in our hospital were randomly divided into the observation group（n=44） and the control group（n=43）. The control group was given magnesium valproate, and the observation group was given lamotrigine on the basis of the control group. Two groups were treated for 6 months. The clinical efficacy, the quality of life（QOLIE-31） score and the incidence of adverse reactions were compared between the two groups. Results Compared with the control group, the curative effect of the observation group was more remarkable, and the total effective rate was 93.18%（41/44）, which was higher than that of the control group 76.74%（33/43）（P〈0.05）. There was insignificant difference between the two groups in the QOLIE-31 score before treatment（P〉0.05）. But after the treatment, the scores of both groups were significantly improved（P〈0.05）, and the observation group was higher than the control group（P〈0.05）. There was insignificant difference between the two groups in the incidence rate such as nausea/vomiting, diarrhea, anorexia, dizziness/headache（P〉0.05）. Conclusion Combination of magnesium valproate and lamotrigine in the treatment of epilepsy has got obvious curative effect. It can effectively improve the quality of life of patients with a certain safety.